Skip to main content
. 2018 Aug 7;9:1826. doi: 10.3389/fmicb.2018.01826

FIGURE 5.

FIGURE 5

Oximacro® interacts with the recombinant extracellular domain of IAV HA. (A) SDS–PAGE and immunoblot analysis of recombinant IAV-HA glycoprotein. Purified HA protein was analyzed on 10% SDS-polyacrylamide gels. Gel was either stained with Coomassie blue or analyzed by immunoblotting with an anti-HA IAV mAb. Left panel: Coomassie blue-stained gel of 1 g of purified recombinant HA-IAV. Right panel: Immunoblot analysis with 200 ng of the same sample as in the left panel. (B,C) Oximacro® interacts with recombinant HA in a concentration- (B) and time-dependent (C) manner. (B) Purified recombinant HA-IAV (1 g) was incubated at 37°C with medium or increasing amounts of Oximacro® for 3 h, and then mixtures were analyzed by SDS–PAGE. (C) Purified recombinant HA-IAV (1 g) was incubated at 37°C for various lengths of time with medium or 6 g of Oximacro®. At 30 min, 1, 2, and 3 h of incubation, mixtures were analyzed by SDS–PAGE. Gels were then stained with Coomassie blue. Sizes are indicated in kilodaltons.